Sony hosted a panel discussion at International Society for Cell and Gene Therapy (ISCT) 2023 where we had distinguished panelists take part in a roundtable discussion on strategies for managing factors affecting cell therapy efficacy. The participants explored the specific T-cell attributes contributing to the performance of adoptive T-cell transfers, and the influence of different methods for cell isolation – such as magnetic bead-based and flow sorting – on the reproducibility and automation of the therapeutic manufacturing workflow. The various parameters affecting CAR-T efficacy were also put in the spotlight, and the advantages and disadvantages of different technologies for controlling T-cell phenotypes were debated.
Sony Biotechnology shared the stage with scientific leaders from Sangamo Therapeutics, France, working on development of a proprietary CAR-Treg manufacturing process, at Advanced Therapeutics Week event in Miami in early 2023. At this event, representatives from the two companies discussed the challenges of isolating rare regulatory T-cells, the advantages of Sony’s CGX10 Cell Isolation System – including closed system technology, high cell purity, higher sorting speed efficiency, data integrity, and compliance with GMP standards – and the potential of CAR-Treg cell therapy for improving outcomes in organ transplantation.
Human induced pluripotent stem cells (iPSCs) offer limitless expansion and differentiation potential into any cell type, holding promise as a versatile therapeutic tool. However, there is a need for a GMP cell sorting system that can purify differentiated cells and remove undifferentiated iPSCs from the final product. Sony Biotechnology, in collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM), Toronto, Canada, recently used its CGX10 Cell Isolation System to isolate and enrich a sample of differentiated cardiomyocytes by removing iPSCs from the solution. The study demonstrated successful multiparametric isolation of the desired target cells at high purity, without compromising cell viability.
CAR-T therapy is a revolutionary technology that can modify a patient’s immune system, offering great potential as a novel therapeutic. Manufacturing these treatments requires the isolation of a rare population of T-cells, and minimizing contamination with other subtypes presents a key challenge. Sony Biotechnology recently conducted a study to investigate the potential of the CGX10 Cell Isolation System to isolate naïve T-cells using multiparametric selection. This cell isolation technology was easily integrated into a closed CAR-T manufacturing process, and successfully sorted rare cell populations using multiple immunological markers.
Innovative flow cytometry-based cell sorting technologies are revolutionizing CGT research, and empowering pharmaceutical companies to advance the manufacture of potent, adoptive therapies using high purity cell isolation and selection. Dr Aditi Singh, Global Senior Product Manager at Sony Biotechnology, recently spoke to David McCall, Editor of Cell & Gene Therapy Insights, to explain how the CGX10 Cell Isolation System can transform this market by enabling GMP-ready cell sorting for clinical-grade CGT. “The CGX10 instrument, with its unique and proprietary microfluidic chip and built-in temperature control cabinet, enables closed, high speed, high purity, multiparametric, fluorescence-based cell sorting for all kinds of CGT manufacturing workflows,” Aditi explained.
Sony Group Corporation today announced that it has been named one of the “World’s Most Ethical Companies” for the fifth consecutive year by the Ethisphere Institute, the US-based global leader in defining and advancing the standards of ethical business practices.
This year’s list includes 135 companies from across 19 countries and regions, and 46 industries. These companies were evaluated across five categories: Governance, Leadership and Reputation, Ethics and Compliance Program, Culture of Ethics, Environmental and Societal Impact. The Institute reviewed each company’s ethical operations, focusing on areas such as exceptional leadership and a commitment to business integrity through best-in-class ethics, compliance, and governance practices.
